ex vivo PAH autologous fibroblasts based gene therapy (Castle Creek Biosciences)

N/A

Report date: 2025/03/20 15:54:13

Base Information

Drug Nameex vivo PAH autologous fibroblasts based gene therapy (Castle Creek Biosciences)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionPhenylalanine hydroxylase stimulants
TargetsPhenylalanine hydroxylase
Therapy Area/IndicationsPhenylketonurias
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesCastle Creek Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesCastle Creek Biosciences Inc
Inactive CompaniesN/A
Active IndicationsPhenylketonurias
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A